Samsung Biologics announces 3 trillion won rights offering

Samsung Biologics plans to raise 3 trillion won through a rights offering to fund capital expenditures and operational expansion. The move signals a significant liquidity injection for the firm, though the impact on existing shareholder equity remains a point of market scrutiny.